HTFL — Heartflow, Inc. Common Stock stock price, charts and financials

NASDAQ·Healthcare·Medical - Healthcare Information Services·USA

Latest market price

27.28

+0.52+1.94%

Overview Short InterestFilings

HTFLQT31Heartflow, Inc. Common Stock·NASDAQ

Overview Short InterestFilings

27.28+1.94%

Analyst

Up 1.9% — Baird initiated coverage at Outperform, price target $34.

Medium confidence

Loading chart...

Screen all →

PGNY-0.16%$31.48 WGS+4.48%$70.90 PRVA+0.00%$23.79 DOCS+1.06%$21.89 WAY+4.90%$23.77 CERT-4.65%$7.80 TDOC+0.45%$6.71 OMDA-1.61%$20.18

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.88	Insider Own	14.26%	Shs Outstand	86.24M	Perf Week	6.60%

Market Cap	2.35B	Forward P/E	-	EPS next Y	-0.27	Insider Trans	-35.82%	Shs Float	66.31M	Perf Month	0.63%

Enterprise Value	2.21B	PEG	-	EPS next Q	-0.14	Inst Own	-	Short Float	8.86%	Perf Quarter	-5.77%

Income	-111.00M	P/S	12.32	EPS this Y	44.76%	Inst Trans	-	Short Ratio	3.93	Perf Half Y	-5.21%

Sales	191.00M	P/B	8.23	EPS next Y	43.68%	ROA	-32.51%	Short Interest	5.87M	Perf YTD	-6.42%

Book/sh	3.32	P/C	14.89	EPS next 5Y	-	ROE	830.46%	52W High	41.22 -33.82%	Perf Year	-

Cash/sh	1.83	P/FCF	-	EPS past 3/5Y	-	ROIC	-21.94%	52W Low	20.13 35.52%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	78.06%	Volatility	5.52% 5.98%	Perf 5Y	-

Dividend TTM	-	EV/Sales	11.60	EPS Y/Y TTM	42.48%	Oper. Margin	-35.83%	ATR (14)	1.71	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	5.57	Sales Y/Y TTM	51.59%	Profit Margin	-58.42%	RSI (14)	51.76	Recom	2.14

Dividend Gr. 3/5Y	-	Current Ratio	5.57	EPS Q/Q	-33.33%	SMA20	6.07%	Beta	1.72	Target Price	37.00

Payout	0.00%	Debt/Eq	0.05	Sales Q/Q	43.24%	SMA50	-5.51%	Rel Volume	0.42	Prev Close	26.76

Employees	843	LT Debt/Eq	0.05	Earnings	Aug 13	SMA200	-6.26%	Avg Volume	1.46M	Price	27.28

IPO Date	Aug 07, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.73% 5.80%	Net Debt/EBITDA	-0.07	Volume	615,794	Change	1.94%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-31-26	Initiated	Baird	Outperform	$34
Jul-15-26	Reiterated	Stifel Nicolaus		$35 → $40
May-15-26	Reiterated	Canaccord Genuity	Buy	$35 → $37
May-15-26	Reiterated	Wells Fargo	Overweight	$38 → $37
Jan-28-26	Initiated	Wells Fargo	Overweight	$38
Sep-02-25	Initiated	Morgan Stanley	Equal Weight	$35
Sep-02-25	Initiated	Canaccord	Buy	$35
Sep-02-25	Initiated	Stifel	Buy	$35
Sep-02-25	Initiated	Piper Sandler	Overweight	$38

Latest News

Jul-31-26

Jul-31-2609:12AM

This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga

07:51AM

Here Are Friday’s Top Wall Street Analyst Research Calls: Blackstone Mortgage, Boston Scientific, Edison International, Ford, GoDaddy, International Paper, Roblox, Saia, and More247wallst.com

Jul-15-26

Jul-15-2608:10AM

What Does the HeartFlow CEO's Sale of Over 20,000 Company Shares Mean for Investors?fool.com

Jul-11-26

Jul-11-2611:10PM

HeartFlow: A Premium AI Diagnostics Storyseekingalpha.com

Jul-09-26

Jul-09-2608:00AM

New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Managementglobenewswire.com

Jul-08-26

Jul-08-2605:21PM

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?fool.com

Jul-04-26

Jul-04-2609:44AM

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?fool.com

Jul-01-26

Jul-01-2604:45AM

Freedom Capital Markets Initiates Coverage On HeartFlow with Buy Rating, Announces Price Target of $37Benzinga

Jun-19-26

Jun-19-2609:00PM

These stocks are moving in today's after hours sessionChartMill

Company

HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023
Total Revenue	191	176	126	87
Cost of Goods Sold Incl. D&A	42	41	31	29
Gross Profit	149	135	94	58
Selling, General and Administrative Excl. Other	145	134	112	95
Research and Development	73	65	44	36
Other Operating Expense	0	0	0	0
Operating Income	-69	-64	-61	-73
Interest Expense	10	15	23	25
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	-33	-38	-12	3
Net Income Before Taxes	-112	-117	-96	-95
Income Taxes	0	0	0	1
Consolidated Net Income	-111	-117	-96	-96
Net Income From Continuing Operations	-111	-117	-96	-96
Net Income	-111	-117	-96	-96
EPS (Recurring)	-0.88	-0.32	-1.53	-1.94
EPS (Basic, Before Extraordinaries)	-0.88	-0.32	-1.53	-1.94
EPS (Diluted)	-0.88	-0.32	-1.53	-1.94
EBITDA	-92	-93	-65	-63
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	—	—	—	—
Price To Sales Ratio	52.70	61.12	—	—
Gross Margin	78.01	76.70	74.60	66.67
Operating Margin	-36.13	-36.36	-48.41	-83.91
Net Margin	-58.12	-66.48	-76.19	-110.34
Shares Outstanding	369	369	63	64
Market Capitalization	10,066	10,756	—	—
Operating Lease Expense	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farquhar John C.M.	Chief Executive Officer	Jul 30 '26	Option Exercise	5.06	31,220	158,013	466,593	Jul 31
Verghese Vikram	Chief Financial Officer	Jul 27 '26	Option Exercise	2.22	22,522	49,999	255,898	Jul 28
Lightcap Jeffrey C	Director	Jul 24 '26	Option Exercise	19.00	47,420	900,980	293,681	Jul 28
BARABE TIMOTHY C	Director	Jul 22 '26	Option Exercise	19.00	3,710	70,490	188,231	Jul 24
Verghese Vikram	Chief Financial Officer	Jul 21 '26	Option Exercise	2.22	22,522	49,999	233,376	Jul 23
BARABE TIMOTHY C	Director	Jul 17 '26	Option Exercise	19.00	5,000	95,000	184,521	Jul 20
Rogers Campbell	Chief Medical Officer	Jul 15 '26	Option Exercise	19.00	9,219	175,161	97,950	Jul 17
Rogers Campbell	Chief Medical Officer	Jul 15 '26	Sale	25.72	9,219	237,113	88,731	Jul 17
Farquhar John C.M.	Chief Executive Officer	Jul 10 '26	Sale	27.75	22,562	626,096	435,373	Jul 13
WELDON WILLIAM C	Director	Jul 08 '26	Option Exercise	8.33	51,369	427,905	243,931	Jul 10
Farquhar John C.M.	Chief Executive Officer	Jun 24 '26	Sale	35.00	38,900	1,361,500	457,935	Jun 26
Rogers Campbell	Chief Medical Officer	Jun 15 '26	Option Exercise	2.22	10,000	22,200	88,731	Jun 17
Farquhar John C.M.	Chief Executive Officer	Jun 10 '26	Sale	28.50	22,562	643,017	496,835	Jun 12
Rogers Campbell	Chief Medical Officer	May 18 '26	Option Exercise	19.00	9,219	175,161	87,950	May 20
Rogers Campbell	Chief Medical Officer	May 18 '26	Sale	28.34	9,219	261,266	78,731	May 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.